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Summary of Recent Advances
In recent years, modular and simplified chemical and biological strategies have been developed for
the synthesis and implementation of positron emission tomography (PET) radiotracers. New
developments in bioconjugation and synthetic methodologies, in combination with advances in
macromolecular delivery systems and gene-expression imaging, reflect a need to reduce
radiosynthesis burden in order to accelerate imaging agent development. These new approaches,
which are often mindful of existing infrastructure and available resources, are anticipated to provide
a more approachable entry point for researchers interested in using PET to translate in vitro research
to in vivo imaging.
Introduction
The development of tools to image biological systems with molecular precision has been a
primary goal of chemical biology over the past decade [1]. Increased adaptation of in vitro
techniques and concepts to in vivo imaging will have a huge impact on our understanding of
complex biological processes in human physiology. In this context, positron emission
tomography (PET) provides a powerful non-invasive means of translating molecular tools from
the bench to human imaging in order to evaluate and optimize novel treatment strategies such
as gene therapy, stem cell implantation, advanced drug delivery systems, and new small
molecule pharmaceuticals. The resolution of PET in terms of space and time may not be as
impressive as other imaging modalities, but its chemical specificity and sensitivity are exquisite
—allowing for the direct observation of molecular interactions at picomolar concentrations
with properly designed radiotracers.
Several recent reviews outline the synthetic challenges of incorporating short-lived radioactive
isotopes and developing imaging probes for PET [2••,3-4], and others detail the concepts and
considerations involved in quantifying PET image data [5-6]. Therefore to avoid redundancy,
this review will highlight recent technology and conceptual advances in PET imaging with a
focus on techniques that may allow chemical biologists to rapidly translate in vitro research to
in vivo imaging, thus bridging the gap between basic and clinical research. The review
emphasizes new strategies in radionuclide bioconjugation, such as modular imaging-agent
delivery systems, advancements in PET-based gene expression imaging, and developments in
PET radiotracer synthesis.
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tAvailability of PET (exploiting the infrastructure that exists)
The use of PET in clinical diagnosis, treatment monitoring, and academic research is in a stage
of exponential growth (Figure 1) that has spawned an infrastructure of isotope production,
distribution, and imaging centers across the United States. In 2005, it was estimated that 97%
of the people in the U.S. live within a 75 mile radius of a PET imaging location [7]. Competition
to supply these imaging centers has driven down the cost of common isotopes and imaging
agents, including 2-[18F]fluoro-2-deoxy glucose (18FDG) and while there are still limitations
to accessing PET infrastructure, chemical biologists should recognize that short-lived
radioactive isotopes used in PET are available both commercially and through collaboration
to test ideas in their full complexity (i.e. in vivo).
Two recent examples highlight ways of exploiting the existing PET infrastructure for in vivo
imaging. In both cases, 18FDG was used as a synthon for peptide labeling, in one case via direct
condensation of 18FDG with an aminooxy-functionalized peptide [8], and in the other by
indirect means via a maleimide intermediate [9]. Bear in mind, 20 mCi of 18FDG can be
delivered to a research site from a commercial vendor for under $300. With proper planning,
this amount of radioactivity can be used for dozens of animal imaging/biodistribution
experiments. Unfortunately, there are a few drawbacks to these methods that may prevent their
immediate use in high specific activity applications, since 18FDG is not separated from glucose
during commercial synthesis. Undoubtedly, as additional refinements are made,
employing 18FDG as a synthon will enable researchers not formally trained as radiochemists
to utilize PET imaging.
“Kit-like” methods for peptide and protein labeling
Along these same lines, new “kit-like” methods have been devised for protein labeling with
[18F]fluoride, which are envisioned to reduce the radiosynthesis burden thus providing PET
access to a larger community (Figure 2). Methods specifically designed to address issues in
PET radiochemistry include 18F/19F isotopic exchange of a silicon-fluoride bond [10,11],
capture of aqueous [18F]fluoride with arylboronic esters [12,13•], and most recently formation
a stable Al18F-chelate bound to a peptide [14••]. The goal of these methods is to simplify protein
and peptide labeling by eliminating the somewhat arduous and lengthy synthesis of a protein
reactive functional group. Both the boron- and aluminum-based methods use aqueous fluoride,
which is clearly advantageous given that [18F]fluoride is produced by a nuclear reaction [18O
(p,n)18F] in isotopically enriched water; however, none of the methods operate within the
narrow window of pH and temperature conditions necessary to preserve the structure and
function of most proteins and the methods require relatively large amounts of substrate to drive
the labeling reaction forward.
These issues are not insurmountable and may be overcome in the future by using innovative
strategies like enzymatic 18F-fluorination to produce protein-reactive 18F-molecules or
potentially to label proteins with 18F directly. Enzymatic labeling with 18F has already been
demonstrated as an elegant technique to produce 18F-nucleosides [15,16•]. Other advances in
PET radiochemistry for peptide and protein labeling, such as click chemistry, originated as
adaptations of general bioconjugation strategies [17-18] will also push the field forward.
Simplification of 18F-bioconjugation strategies and the development of methods to purify
labeled biomolecules from unlabeled reagents will be an area of tremendous growth in the
coming years.
Modular Approaches and Advanced Delivery Strategies
Developments in PET imaging agent delivery systems have paralleled advances in drug
delivery strategies [19]. Given that each potential biological imaging agent introduces a unique
set of synthetic constraints for radionuclide incorporation, modular strategies are being
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tdeveloped that decouple radionuclide labeling from biomolecule identity. The fundamental
goal of this work is to provide a general platform that consists of at least two elements: 1) a
targeting group such as a peptide to direct the imaging agent to a particular cellular target or
tissue of interest and 2) a chemically independent functional handle for radionuclide
incorporation, (Figure 3). The dual component design of these modular imaging agents offers
several advantages, including the potential to display multiple copies of a targeting moiety
(thus increasing its affinity) and the ability to modify of the imaging agent shell to alter its
pharmacokinetics and in vivo stability. It is anticipated that these platforms could readily afford
imaging agents for a range of biomedical applications while reducing redundancy in chemical
optimization.
The flexibility of a modular synthesis allows researchers access to two distinct types of in
vivo information provided by PET: 1) the disposition (pharmacokinetics and distribution) of a
compound (e.g. drug molecule, protein, delivery scaffold); and 2) the characterization of a
physiological parameter (e.g receptor concentration/occupancy, enzyme activity, metabolism,
or gene expression). PET imaging can based on a modular platforms can accomplish either or
both depending the desired information and the design of the platform.
Although many research groups have developed modular platforms for imaging agents, only
a few illustrative examples will be referenced here. The collaborative efforts of the Welch
group at Washington University have led to several modular PET imaging agents. With the
Wooley group, shell cross-linked knedel-like (SCK) nanoparticles were labeled with 64Cu
using DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) as a chelating ligand,
enabling the authors to explore the effect of nanoparticle size, core material, and flexibility on
biodistribution [20-21]. The original labeling method placed the radionuclide on the exterior
of the surface of the nanoparticle; however, more recently the authors were able to
move 64Cu-chelate to the interior of the SCK nanoparticles by using amphiphilic block
copolymers [22••]. Using this more tunable chemical strategy, the surface of the nanoparticle
was modified with various densities of methoxy-terminated poly(ethylene glycol) (mPEG).
With this system, a mathematical model was developed to describe how mPEG density, and
the corresponding hydrodynamic volume, affects circulation half-life in vivo. Analogous
studies using a core-shell star copolymer labeled with 64Cu confirmed that a modular polymer-
based system could be used to tune biodistribution [23]. These fundamental studies are
important as they provide general guidelines for the development and optimization of PET
imaging agent and drug delivery systems.
Biodegradable core-shell systems, which may minimize scaffold accumulation and toxicity,
have been developed for PET radionuclide delivery based on protein assemblies and
dendrimers. For example, the 27 nm hollow protein shell of bacteriophage MS2 was modified
through a series of chemical reactions resulting in 18F-incorporation on the interior surface of
the virus. By co-modification of the interior surface of the virus with a fluorescent dye, the
authors demonstrate that the protected “cargo” on the interior surface does not alter
biodistribution [24•]. In a synthetic equivalent using a biodegradable dendritic nanoprobe
targeted to αvβ4 integrin and labeled with positron emitting bromine-76, Fréchet and coworkers
have demonstrated that multivalent macromolecular delivery systems can address imaging
targets, such as angiogenesis, which have not been addressed effectively with small molecule
approaches [25].
As evidenced by the work described above with 64Cu, metal-chelating groups and positron
emitting metal isotopes can be employed as facile and reliable components of modular imaging
probes [26]. Consequently there is ongoing work to improve the stability of radiometal
complexes for peptide, protein, and macromolecule labeling. As an example, a very promising
divalent imaging probe was recently constructed using an ethylene cross-bridged tetraamine
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tligand that forms a neutral octahedral complex with 64CuII [27]. In addition to new chelating
ligands, improved methods for generating PET isotopes that are mobile, self-contained, and
commercially available will drive advancements in modular imaging approaches. For instance,
the use of generator-produced gallium-68, which is independent of cyclotron availability, has
rapidly increased over the past few years [28-29].
Imaging Gene-Expression in vivo with PET
Imaging gene-expression with PET is a research area rife with unrealized potential, as it would
confer the benefits of near-perfect target fidelity, wide applicability to proteins, and broad
versatility arising from its modularity at the genetic level (Figure 3). PET reporter systems can
be thought of as in vivo correlates of what are now conventional reporter systems, such as green
fluorescent protein (GFP) and luciferase, which are used routinely in vitro for cellular imaging
and increasingly for in vivo imaging [30,31]. Due to its high sensitivity and tissue-penetrant
radiation, PET-based gene-expression imaging may have offer advantages over optical
imaging methods for human translational research, particularly research related to the brain.
Since its conception roughly a decade ago, noninvasive reporter gene imaging with PET has
been refined steadily [32-33••] and used recently in many exciting applications [34-35].
The most common reporter systems have been based on the variations of the herpes simplex
virus type 1 thymidine kinase (HSV1-tk), which can be introduced to specific cells by retroviral
infection. A major limitation to the use of PET imaging for monitoring gene-expression in this
case has been the development of radiotracers that act as substrates for HSV1-tk and upon
phosphorylation are trapped in the cells expressing the reporter gene. The most promising
candidates, such as [18F]FEAU (2′-[18F]fluoro-2′deoxy-5-ethyl-1-β-D-arabinofuranosyluracil)
and [18F]FHBG (9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine), suffer from challenging
low yielding multi-step syntheses that in many case require more than 3 h [36]. Despite a
growing effort to improve the reporter enzyme [37], the lack of suitable and readily accessible
PET radiotracers remains an unsolved problem for HSV1-tk-based systems as well as other
enzyme-based reporter systems such as LacZ [38].
Although there have been limited human trials with HSV1-tk PET [39-40], HSV1-tk and
mutants derived from it are not endogenously expressed in humans and may present
immunogenicity issues. Therefore, there is an ongoing effort to identify gene-reporter systems
based on human proteins [41] such as the norepinephrine transporter [42], the sodium iodide
symporter [43], and human mitochondrial thymidine kinase 2 [44]. As the challenges in
optimizing reporter/radiotracer pairs and radiotracer synthesis are overcome (and perhaps a
commercial radiotracer is realized), PET gene-expression imaging may become a
transformative tool in biomedical research.
New chemistry will accelerate the use of PET
Although the focus of this review has been on modular, largely macromolecular, approaches
to PET imaging, we cannot ignore that small-molecule radiotracers will continue to play the
dominant role in human imaging. Thus, it is worth noting that the concepts of modularity,
process simplification, and expanded use of existing PET infrastructure can and should apply
to very fundamental advances in small molecule radiotracer synthesis. Although this is true
for chemical methods developed for any short-lived isotope, we will use a few recent examples
of new carbon-11 labeling methods to illustrate this point [2,45].
[11C]Carbon monoxide is an incredibly appealing synthon for metal-catalyzed carbonylation
reactions that has yet to reach its full potential in radiotracer synthesis because of its limited
solubility in organic solvents, which complicates trapping and limits chemical reactivity.
However, it was recently shown that copper(I) scorpionate complexes can be used to trap and
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trelease 11CO at atmospheric pressure with incredible efficiency, and can be used in situ as
a 11CO donor for Pd-mediated reactions [46•]. This process simplification and its future
refinements will open the door for many PET radiotracer chemists to use 11CO and inevitably
in new reaction scenarios.
New developments involving other one-carbon synthons have also paved the way for more
facile synthesis of carbon-11 radiotracers without the need for new equipment, exotic reagents,
or complex processes. In particular, two methodologies with broad applications have been
developed by our research group. The first takes advantage of 11CO2, the product of the nuclear
reaction [14N(p,α)11C], which is the starting point for nearly all carbon-11 chemistry. After
capturing 11CO2 in solution with DBU (1,8-diaza-bicyclo[5.4.0]undec-7-ene), we demostrated
that [11C]carbamates can be formed in high radiochemical yields from an amine and alkyl
halide. The reaction set-up was extremely simple consisting of one vessel, occured at relative
low temperatures, and had a wide substrate tolerance thus allowing [11C]carbamates to be
“stitched” together in modular fashion [47]. A second new methodology uses 11CH3I—the
predominant labeling reagent in use today - to access to [11C]formaldehyde through conversion
with trimethylamine-N-oxide [48•]. While this route might not seem intuitive, it takes
advantage of a highly optimized building block already available (11CH3I) rather than starting
from scratch and thus immediatly provides a new synthon to carbon-11 radiochemists.
Recognizing and utilizing available tools is an important design consideration for new
methodology that will facilitate the transition of a new method from initial description to
routine use.
Conclusions
As the use of PET continues to increase and expand in scope over the next decade, new
strategies in radiotracer design and synthesis will be required that decrease the barriers involved
in radiochemistry and allow more researchers to utilize PET imaging. As with any technology,
the associated costs will go down, PET isotopes and scanners will become more available, and
distribution centers will continue to sprout. As this occurs and PET becomes available to a
more diverse research community, chemists developing new methods must begin to think
carefully about how to place PET radiotracers in the hands of more end users, so that access
to radiotracers does not impede PET utilization. While automation and engineering will play
a key role in providing access [49-50], exploitation and clever use of existing infrastructure
combined with an expansion of modular strategies and chemical transformations like those
described in this review will no doubt increase the types of studies that can be performed.
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tFigure 1. Exponential growth of PET
Number of year-limited publication hits for “positron emission tomography” using the Scopus
abstract and citation database.
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Key features of macromolecule imaging agents. Regardless the specific design,
macromolecular approaches feature tunable independent surfaces for targeting and
radionuclide incorporation. Multivalency can be used to both amplify affinity for a target and
increase the overall specific radioactivity of an agent.
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Reporter gene methods used in PET
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